Saturday, 3 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 27, 2026

FullPAC, Inc. Issues Spring 2026 Chairman’s Letter

View original at globenewswire.com
FullPAC, Inc. Issues Spring 2026 Chairman’s Letter Virginia Beach, VA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- FullPAC, Inc. (“FullPAC” or the “Company”) (Nasdaq Reserved: GOTV), a premier nonpartisan campaign technology provider for more than 5,000 U.S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FullPAC is well positioned to serve the growing political spending market as campaign investment builds ahead of the 2028 Presidential election

    80% confidence

  • Advocacy Lab contributes meaningful recurring revenue and serves as a natural entry point into the broader FullPAC platform, strengthening client retention and expanding long-term revenue opportunities

    80% confidence

  • FullPAC is positioned to become the premier public-market pure play on America's growing political campaign industry

    80% confidence

  • Cash flows from Advocacy Lab will cover its direct purchase consideration by March 31, 2026, several months ahead of schedule

    80% confidence

  • Political campaign spending has surged ever higher since Citizens United was decided in 2010

    80% confidence

  • The 2026 election cycle's projected $10.8 billion advertising spending makes it the most expensive non-presidential election cycle in history, marking a more than 20% increase over 2022 midterms

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com